Mitochondrial dysfunction in nonalcoholic steatohepatitis.
about
The Emerging Role of Disturbed CoQ Metabolism in Nonalcoholic Fatty Liver Disease Development and ProgressionRegulation of mitochondrial function by voltage dependent anion channels in ethanol metabolism and the Warburg effectMolecular Pathogenesis of NASHLabel-Free Proteomics Assisted by Affinity Enrichment for Elucidating the Chemical Reactivity of the Liver Mitochondrial Proteome toward Adduction by the Lipid Electrophile 4-hydroxy-2-nonenal (HNE)Effects of resveratrol in experimental and clinical non-alcoholic fatty liver diseaseModern approach to the clinical management of non-alcoholic fatty liver diseaseNonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective.Ketogenesis prevents diet-induced fatty liver injury and hyperglycemiaCurcumin prevents the non-alcoholic fatty hepatitis via mitochondria protection and apoptosis reductionElectron Therapy Attenuated Elevated Alanine Aminotransferase and Oxidative Stress Values in Type 2 Diabetes-Induced Nonalcoholic Steatohepatitis of Rats.In Situ Evaluation of Oxidative Stress in Rat Fatty Liver Induced by a Methionine- and Choline-Deficient DietGenetic Variation in Human Vitamin C Transporter Genes in Common Complex Diseases.Lipoic Acid prevents the changes of intracellular lipid partitioning by free Fatty AcidNeuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELASEffects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approachSphingolipids and mitochondrial function, lessons learned from yeastInflammation and fibrogenesis in steatohepatitis.Nonalcoholic fatty liver disease and bariatric surgery.Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities.Exercise as a therapeutic tool to prevent mitochondrial degeneration in nonalcoholic steatohepatitis.Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation.Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver disease.A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice.Exercise mitigates mitochondrial permeability transition pore and quality control mechanisms alterations in nonalcoholic steatohepatitis.
P2860
Q26775025-30A52D71-783C-4AB9-B409-A9481BC272A9Q26827829-140478A8-5E29-4E7C-B0B6-02B295698190Q28071265-8C70874E-FC5A-40FB-ACDD-98C220A86701Q28834332-AE87D6D1-2772-4B20-A4B2-BA8B1526AB51Q33563877-36B73128-E553-4470-8161-FB3469735566Q33886923-B0928633-E4FC-4923-9A9A-6F483AFB53DBQ34412650-F14FFA23-4906-49F9-B28C-4C106AFF6704Q35145496-E518056A-532E-43A9-A602-249043B7477CQ36261892-2F40340D-DD10-471C-81E9-560E48CC7DDBQ36528728-A6B698C2-3098-4AE5-9F3C-DE63D7104275Q36531596-B57F6D0D-541E-4F28-B5BA-8A9FAB89EE97Q36670980-2599F8A4-A60D-4030-A937-B1841F40FF2BQ36715146-B2DB7CB9-C4F6-486E-BCA4-5C9ABCEB8B23Q36762830-D5EC7347-8B28-42EE-A39D-BD874983FF53Q37262700-F0261F9C-74ED-45CC-940D-E2309CB391F7Q37698292-A936ED85-67A6-4C80-A2BB-759F9F69E34DQ37981867-CB2E751C-D2AF-4952-A6CB-17E722C8B9AAQ37989159-200110A9-EB7A-4432-83D8-51EB424E9AE5Q38093566-4F38E47B-E5B7-4042-84D8-289E8EE372C6Q38137185-92865EB3-4FD4-4B2F-A660-5D19937022A7Q39126658-B7FFF6C3-900F-47BA-9846-79983799CA4BQ39266499-106CB0E2-16BF-4054-92A5-1776E532811FQ41152963-6ED01C06-219B-4E61-8274-4A40F0DED734Q46063164-1C9A1BB0-E177-427B-A816-0263EF024848Q46413321-4D6EB15E-D667-425C-95BB-C8D4A59864A4Q47103439-8BA82B76-5299-4605-9F9A-09B834CE7093Q49785252-B1AF11C2-093B-4C2C-8CBD-AEC958BEB682Q50877201-6F5AD50F-A976-4F69-A216-4AAF299C4B01
P2860
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@en
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@nl
type
label
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@en
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@nl
prefLabel
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@en
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@nl
P2093
P2860
P356
P1476
Mitochondrial dysfunction in nonalcoholic steatohepatitis.
@en
P2093
Emanuele Altomare
Francesco Bellanti
Gaetano Serviddio
Gianluigi Vendemiale
P2860
P304
P356
10.1586/EGH.11.11
P577
2011-04-01T00:00:00Z